We found that the combination of low dose anti-TNFα associated with mucosal tolerization to the arthritogenic T cell epitope led to a significant reduction of arthritis clinically as well as histologically, to a degree entirely comparable with what was achieved with full dose anti-TNFα. This evidence concerns the gene TNF and arthritic joint disease.